Last updated: April 24, 2026
Who Supplies Brinzolamide (and What to Source by Function)?
Brinzolamide is a generic ocular carbonic anhydrase inhibitor used in products such as Azopt® (brinzolamide 1% ophthalmic suspension) and multiple glaucoma formulations. Supplier coverage in this space is typically split into two functional buckets: API (active pharmaceutical ingredient) manufacturers and formulation/finished-dose manufacturers (including ophthalmic sterile fill-finish). Below is the supplier map you should use for sourcing and due diligence for brinzolamide.
Which Suppliers Provide Brinzolamide API?
Below are commonly used brinzolamide API sourcing targets by manufacturer identity you can qualify through DMF filings, audit history, and regulatory listings. API supply chains for brinzolamide are dominated by China and India, with additional EU/US partnerships for commercialization.
API supplier targets (qualification list):
- Chongqing Taiji (China)
- Lunan Pharmaceutical (China)
- Hubei Huarong Pharmaceutical / Hubei Huarong (China)
- Sino-US / local China brinzolamide-API producers (China)
- Cognis-like specialty intermediates producers (India/China networks that supply brinzolamide building blocks, then contract API step completion)
- Generic API houses in India that support ophthalmic CA inhibitor APIs (India)
Practical sourcing checks for brinzolamide API:
- Request CoA and EDQM/USP equivalence where relevant to your target market (US: USP, EU: Ph.Eur).
- Confirm the salt form is not applicable: brinzolamide is supplied as the free base (not a salt) in typical ophthalmic suspensions.
- Require documentation for:
- Particle size specification for suspension performance
- Residual solvent profile
- Impurity panel (process impurities)
- Sterility is not an API requirement, but the API grade must support sterile final product manufacturing.
Which Suppliers Do Ophthalmic Finished-Dose Manufacturing (Sterile Fill-Finish)?
Brinzolamide is commonly supplied as a sterile ophthalmic suspension. For finished dose sourcing, buyers typically split work across:
1) sterilization-grade suspension formulation development,
2) sterile fill-finish, and
3) packaging (dropper bottle + carton).
Finished-dose manufacturer targets to qualify (sterile ophthalmics):
- US/EU ophthalmic sterile fill-finish specialists (for branded or US-EU compliant supply)
- India sterile ophthalmics OEMs with ophthalmic CGMP lines
- China sterile ophthalmics OEMs with regulatory track record and controlled aseptic processing
Due diligence items that matter specifically for brinzolamide suspensions:
- Aseptic processing method and batch sterility assurance
- Suspension rheology and settling control
- Valve compatibility for eye-drop containers
- Uniformity testing for drug content through storage time
- Extractables and leachables (container closure system)
What Is the Standard Commercial Supply Form for Brinzolamide?
For ophthalmic products, brinzolamide is supplied and formulated as:
- API: brinzolamide (free base)
- Finished drug: 1% brinzolamide ophthalmic suspension (typical reference concentration)
Key downstream requirements:
- Sustained suspension performance
- Visual homogeneity on shaking
- Predictable droplet delivery from ophthalmic dosing devices
How to Build a Short-List for Procurement (API vs OEM)?
If you need only API (batch manufacturing or contract formulation):
- Qualify 2 to 3 API sources with DMF/ASMF documentation readiness.
- Use batch-to-batch impurity consistency metrics.
- Lock down specifications that affect suspension outcomes (particle size, moisture, residual solvents).
If you need finished product (regulatory-ready supply):
- Qualify one OEM for sterile fill-finish.
- Confirm experience with ophthalmic suspension rather than solution-only lines.
- Validate packaging and shelf-life data aligned to your target label.
Procurement Checklist: What to Request from Any Brinzolamide Supplier
From API suppliers
- DMF/ASMF status (where applicable)
- Specification sheet: assay, related substances, particle size, moisture, residual solvents
- CoA for 3 consecutive batches
- Change control commitments (process, impurity, polymorph if applicable)
- Lead time for commercial and scale-up lots
From finished-dose suppliers
- Sterile manufacturing control strategy
- Batch manufacturing record summary and deviation history
- Container closure system validation package
- Stability protocol and ongoing stability results
- Shipping conditions and temperature excursions policy
Key Takeaways
- Brinzolamide sourcing is best organized into API suppliers and ophthalmic sterile fill-finish OEMs, because suspension performance depends on particle properties and aseptic processing.
- Short-list multiple API sources to secure supply continuity and control impurity consistency.
- For finished-dose procurement, prioritize ophthalmic suspension experience and validated sterile fill-finish plus container closure system compatibility.
FAQs
-
Is brinzolamide supplied as a salt for ophthalmic products?
No. Brinzolamide is typically supplied as the free base in ophthalmic suspensions.
-
What matters most when buying brinzolamide API for suspensions?
Particle size and impurity consistency, because they drive suspension uniformity and performance.
-
Can a general sterile injectables OEM handle brinzolamide ophthalmic suspension?
Not by default. Ophthalmic suspension manufacture has specific formulation and fill-finish controls.
-
Do suppliers typically offer brinzolamide in the exact 1% finished strength?
Many do as finished product, but some supply only API for contract formulation and sterile fill-finish by another party.
-
What documentation should be mandatory before placing a long-term supply contract?
API CoAs across multiple batches plus full specification sheets, or for finished dose: sterility assurance package, stability data, and container closure validation.
References
[1] U.S. Food and Drug Administration. Drugs@FDA: Azopt (brinzolamide) label and approval history. FDA.
[2] European Medicines Agency. EPAR and product information for brinzolamide ophthalmic products. EMA.
[3] PubChem. Brinzolamide compound summary. National Center for Biotechnology Information (NCBI).
